Vigabatrin in pediatric patients with refractory epilepsy

Area of Science:

• Pediatric Neurology
• Epileptology
• Clinical Pharmacology

Background:

• Intractable epilepsy in children poses significant treatment challenges.
• Newer antiepileptic drugs offer improved seizure control.
• Vigabatrin (VGB) is a newer generation antiepileptic medication.

Purpose of the Study:

• To evaluate the efficacy and side effect profile of vigabatrin (VGB) in pediatric patients with intractable epilepsy.
• To determine VGB's effectiveness across different seizure types.
• To identify common adverse events associated with VGB treatment.

Main Methods:

• Retrospective review of a short-term video-EEG monitoring laboratory database.
• Screening of pediatric patients with intractable epilepsy on VGB for at least three months.
• Abstraction of clinical data including seizure type, efficacy, and side effects from medical records.

Main Results:

• VGB reduced seizure frequency by at least 50% in 33.3% of patients with partial seizures and 30.6% with primary generalized seizures.
• Complete seizure resolution was observed in six responders with partial seizures.
• Common side effects included visual field defects, increased appetite, and obesity.

Conclusions:

• Vigabatrin demonstrates efficacy in reducing seizure frequency in childhood intractable epilepsy, showing greater effectiveness in partial onset seizures.
• Patients treated with VGB require close monitoring for potential adverse effects, especially visual field defects.